Feb 25, 2026: $CRL agreed to sell its CDMO and Cell Solutions businesses to GI Partners for primarily…
Filed with the SEC on · Summarized by InvestorsBot
Feb 25, 2026: $CRL agreed to sell its CDMO and Cell Solutions businesses to GI Partners for primarily contingent, performance‑based payments. Includes CDMO sites (TN, MD, UK) and Cell Solutions site (CA). Combined 2025 revenue $143M. Close Q2'26 🧬 #M&A #Biotech
Feb 25, 2026: $CRL to divest certain European Discovery Services assets to IQVIA ($IQV) for ~ $145M cash + up to $10M contingent; assets generated $144M in 2025. Five sites across UK, Germany, Finland, Netherlands. Close Q2'26 💰 #M&A #LifeSciences
Impact: Both deals reduce reported 2026 revenue by ~> $200M (~-5%), trim >50 bps off organic growth, but are expected to add ≥100 bps to non‑GAAP operating margin and ~+$0.10 to non‑GAAP EPS (partial year). Updated non‑GAAP EPS: $10.80–$11.30. $CRL 📉 #Guidance #Investing